MedTrace Logo

Predictors of Severe COVID-19 Outcomes

NCT04388813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 494

Last updated 2024-05-28

No results posted yet for this study

Summary

This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.

Conditions

  • Acute Respiratory Distress Syndrome
  • COVID-19

Sponsors & Collaborators

  • Verily Life Sciences LLC

    lead INDUSTRY

Principal Investigators

  • Charlie Kim, PhD · Verily Life Sciences LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-28
Primary Completion
2021-09-23
Completion
2021-09-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04388813 on ClinicalTrials.gov